Street View: Signs of momentum returning to Colgate-Palmolive

Colgate-Palmolive

03/08/2026 11:20

** Colgate-Palmolive CL.N on Friday reaffirmed its annual sales forecast even after posting a quarterly rise as the toothpaste maker continues to grapple with muted demand in North America
** Median PT of 23 brokerages covering the stock is $98.50; average rating "buy" - LSEG-compiled data
     
EMERGING MARKETS EXPOSURE IS KEY
** Morgan Stanley ("overweight," PT: $104) sees underlying sales growth rebounding to 3%-4%, driven by pricing strength, market-share gains in oral care and pet products, and strength in emerging markets (EM)
** Piper Sandler ("overweight," PT: $98) remains bullish on pet portfolio and believes "CL can gain share as it continues to add value through differentiated innovation"
** Jefferies ("hold," PT: $89) says EM demand is strong and CL "remains the best way to play it"
** TD Cowen ("hold," PT: $90) says robust broad-based growth in EM offset the weakness in North America and views Q2 results as strong enough to support the stock's premium valuation
** TD Cowen expects near-term earnings growth to be negatively impacted by rising cost inflation from the Iran war and limited pricing power in developed markets 
     
     

 (Reporting by Joel Jose in Bengaluru)
 ((mailto: JoelJose@thomsonreuters.com))